Antagonist for the Kappa Opioid Receptor - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
Advances in the Treatment of Chronic Pain by Targeting GPCRs | Biochemistry
Frontiers | Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain
Conformational Constraint between Aromatic Residue Side Chains in the “Message” Sequence of the Peptide Arodyn Using Ring Closing Metathesis Results in a Potent and Selective Kappa Opioid Receptor Antagonist | Journal of
Dynorphin Controls the Gain of an Amygdalar Anxiety Circuit - ScienceDirect
Prefrontal Cortical Kappa-Opioid Receptor Modulation of Local Neurotransmission and Conditioned Place Aversion | Neuropsychopharmacology
Cells | Free Full-Text | Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Molecular mechanism of biased signaling at the kappa opioid receptor | Nature Communications
Biomedicines | Free Full-Text | Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity
Antagonist for the Kappa Opioid Receptor - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
Antagonist for the Kappa Opioid Receptor - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
Nalfurafine, a G-Protein–Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics | Hypertension
Direct Selection of DNA-Encoded Libraries for Biased Agonists of GPCRs on Live Cells | JACS Au
Nanobody-enabled monitoring of kappa opioid receptor states | Nature Communications
Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice | Neuropsychopharmacology
Antagonist for the Kappa Opioid Receptor - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
I'll Be Back”: The Resurrection of Dezocine | ACS Medicinal Chemistry Letters
Frontiers | The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
![Standard Opioid Agonists Activate Heteromeric Opioid Receptors: Evidence for Morphine and [d-Ala2-MePhe4-Glyol5]Enkephalin as Selective μ−δ Agonists | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/cn9000236/asset/images/medium/cn-2009-000236_0007.gif "Standard Opioid Agonists Activate Heteromeric Opioid Receptors: Evidence for Morphine and [d-Ala2-MePhe4-Glyol5]Enkephalin as Selective μ−δ Agonists | ACS Chemical Neuroscience")
Standard Opioid Agonists Activate Heteromeric Opioid Receptors: Evidence for Morphine and [d-Ala2-MePhe4-Glyol5]Enkephalin as Selective μ−δ Agonists | ACS Chemical Neuroscience
Frontiers | The role of endogenous opioid neuropeptides in neurostimulation-driven analgesia
The receptor hypothesis and the pathogenesis of depression: Genetic bases and biological correlates - ScienceDirect
Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials | Neuropsychopharmacology
Pharmaceuticals | Free Full-Text | In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist
Frontiers | The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
κ-opioid receptor - Wikipedia
